Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30887592 | 0.96 | CASP3 (0.49) | CASP3PIN1KMT2A | |
| SCHEMBL31488367 | 0.92 | CASP3 (0.43) | CASP3PIN1KMT2AMDM4TP53 | |
| SCHEMBL30474403 | 0.91 | KMT2A (0.49) | CASP3PIN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL25268021 | 0.91 | KMT2A (0.49) | CASP3PIN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL25213324 | 0.91 | KMT2A (0.49) | CASP3PIN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL8210873 | 0.89 | CASP3 (0.48) | CASP3PIN1KMT2AMDM4TP53 | |
| SCHEMBL28522099 | 0.89 | CASP3 (0.48) | CASP3PIN1KMT2AMDM4TP53 | |
| SCHEMBL14019298 | 0.89 | POLB (0.51) | CASP3PIN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL31546599 | 0.89 | POLB (0.51) | CASP3PIN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL29477082 | 0.88 | CASP3 (0.47) | CASP3PIN1KMT2ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001836-A1 | METHODS FOR PREPARING (2S,3R,4R)-4,5-DIHYDROXYISOLEUCINE DERIVATIVE AND INTERMEDIATES THEREOF | UNIV INNER MONGOLIA (CN) | 2026-01-01 | — | — | US | disclosed |
| WO-2024188374-A2 | PREPARATION METHOD FOR (2S,3R,4R)-4,5-DIHYDROXY ISOLEUCINE DERIVATIVE AND INTERMEDIATE | 内蒙古大学 | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001836-A1 | METHODS FOR PREPARING (2S,3R,4R)-4,5-DIHYDROXYISOLEUCINE DERIVATIVE AND INTERMEDIATES THEREOF | GRIA4, GRIK4, DHPS | CASP3 3859/4885PIN1 3903/4885KMT2A 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.